Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ulodesine (also known as BCX4208) is a purine nucleotide phosphorylase (PNP) inhibitor being developed by Biocryst for the treatment of gout. Intended as a once-daily oral therapy, it functions by impacting the purine metabolic pathway upstream of xanthine oxidase to decrease serum uric acid (sUA) levels. Its half-maximal inhibitory concentration (IC(50)) for PNP is 0.5 nM. Currently, BCX-4208 is in early clinical trials to evaluate its potential benefits in treating psoriasis and gout.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | Ulodesine (also known as BCX4208) is a purine nucleotide phosphorylase (PNP) inhibitor being developed by Biocryst for the treatment of gout. Intended as a once-daily oral therapy, it functions by impacting the purine metabolic pathway upstream of xanthine oxidase to decrease serum uric acid (sUA) levels. Its half-maximal inhibitory concentration (IC(50)) for PNP is 0.5 nM. Currently, BCX-4208 is in early clinical trials to evaluate its potential benefits in treating psoriasis and gout. |
Alias | Ulodesine, DADMe-immucillin H, BCX-4208, BCX4208, BCX 4208 |
Molecular Weight | 323.325 |
Formula | C12H16N4O3 1/2C4H6O4 |
Cas No. | 1246200-39-4 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.